scholarly journals The European Society of Gynecologic Oncology (ESGO) 19th biannual meeting: Overview and summary of selected topics

2016 ◽  
Vol 140 (3) ◽  
pp. 377-380 ◽  
Author(s):  
Shannon N. Westin ◽  
Leslie Randall
Keyword(s):  
European Society ◽  
Gynecologic Oncology ◽  
Biannual Meeting

Summary of the 18th Biannual Meeting of the European Society of Gynecologic Oncology (ESGO)

2014 ◽  
Vol 132 (2) ◽  
pp. 270-272 ◽  
Author(s):  
Annalisa Garbi ◽  
Nicoletta Colombo ◽  
Giovanni Aletti
Keyword(s):  
European Society ◽  
Gynecologic Oncology ◽  
Biannual Meeting

Utility and Actual Use of European and Spanish Guidelines on the Management of Endometrial Cancer Among Gynecologic Oncologists in Spain

2017 ◽  
Vol 27 (6) ◽  
pp. 1293-1297 ◽  
Author(s):  
Ignacio Zapardiel ◽  
Claudia Blancafort ◽  
David Cibula ◽  
Ibon Jaunarena ◽  
Mikel Gorostidi ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
European Society ◽  
Gynecologic Oncology ◽  
Low Risk ◽  
Intermediate Risk ◽  
Nodal Staging ◽  
International Guidelines ◽  
Cancer Management ◽  
Care Giving ◽  
Paraaortic Lymphadenectomy

ObjectiveThe aim of the study was to analyze the current management of endometrial cancer across Spain and to evaluate the use and applicability of the national and international guidelines.Materials and MethodsAn electronic 30-question survey was distributed among all Spanish Society of Obstetrics and Gynecology–registered specialists dedicated to gynecologic oncology in Spain by e-mail. Data were collected anonymously and analyzed using SPSS program.ResultsOne hundred forty-five (17.8%) surveys were collected. Significant differences were observed between tertiary hospitals and secondary or private hospitals in terms of appropriate (according to European Society of Gynaecologic Oncology guidelines) nodal staging in low-risk cases (96 [95%] vs 27 [61.4%], respectively; P < 0.001), appropriate nodal staging in intermediate-risk cases (96 [95%] vs 39 [88.6%], respectively; P = 0.004), appropriate treatment in advanced-stage cases (63 [67.7%] vs 13 [40.6%], respectively; P < 0.001), and surgical treatment of relapses (87 [93.5%] vs 18 [56.3%], respectively; P = 0.004) but nonsignificant in the rate of complete paraaortic lymphadenectomy performance (82 [81.2%] vs 28 [63.6%], respectively; P = 0.056). Similar results have been observed when comparing centers with less than 20 cases per year to centers with more than 40 cases annually, with significant differences in the management of low-risk and intermediate-risk endometrial cancers.ConclusionsThis cross-sectional study demonstrates a broad heterogeneity of care giving between the clinical national and international guidelines and the actual practice in Spain. Although most of the responders refer to base their endometrial cancer management on Spanish and European Society of Gynaecologic Oncology guidelines (64.1%), many discrepancies have been observed, mainly in the management of intermediate-risk cases and follow-up. It may be caused by the lack of consensus on certain points, lack of facilities in lower case load centers, and also due to disagreement or unawareness on the current knowledge.

The European Society of Gynaecological Oncology: Update on Objectives and Educational and Research Activities

2012 ◽  
pp. 335-338
Author(s):  
Renata Brantnerova ◽  
Ranjit Manchanda ◽  
Nicoletta Colombo
Keyword(s):  
European Society ◽  
Research Collaboration ◽  
Planning Process ◽  
Gynecologic Oncology ◽  
European Network ◽  
Gynecologic Cancers ◽  
Gynaecological Oncology ◽  
Research Activities ◽  
Oncology Trial ◽  
Poster Presentations

Overview: The European Society of Gynaecological Oncology (ESGO) is the principal European society contributing to the study, prevention, and treatment of gynecologic cancers. Founded in 1983, ESGO has more than 1,300 members in more than 40 European countries and worldwide who benefit from ESGO's innovative education and research initiatives and networking opportunities. ESGO objectives have been recently identified through a strategic planning process and include education, care, research, collaboration, awareness, and sustainability. As a leading gynecologic oncology society, ESGO holds biennial meetings where experts meet to discuss latest advances in gynecologic treatment and care. The 17th International Meeting of ESGO (ESGO 17) proved to be a resounding success, with 2,700 delegates and speakers who gathered from around the world in the cultured city of Milan, Italy. The structure of the congress included keynote lectures, debates, state-of-the art sessions, and focused sunrise sessions, together with oral and poster presentations and satellite symposia sponsored by pharmaceutical companies. For the first time, during ESGO 17 the Society organized a seminar for European patient groups with an interest in gynecologic cancers with the aim of facilitating different patientrelated activities across Europe. Moreover, The European Network of Young Gynaecologic Oncologists (ENYGO), the European Network of Gynaecologic Oncology Trial Groups (ENGOT), and the European Network of Translational Research in Gynaecological Oncology (ENTRIGO) had their own section during ESGO 17. ESGO also holds numerous workshops throughout the calendar year and provides clinical and research grants, online educational materials, webcasts, and numerous networking opportunities

Sign in / Sign up

Export Citation Format

Share Document